Go Pro
→ They're not buying gold. They're buying this. (From Behind the Markets) (Ad)tc pixel Free ATXI Stock Alerts

Avenue Therapeutics (ATXI) Competitors

Avenue Therapeutics logo
$0.54 -0.03 (-4.47%)
As of 01:36 PM Eastern
Compare

ATXI vs. ACXP, CURX, SNOA, RVPH, and ENVB

Should you buy Avenue Therapeutics stock or one of its competitors? Avenue Therapeutics's main competitors and comparable companies include Acurx Pharmaceuticals (ACXP), Curanex Pharmaceuticals (CURX), Sonoma Pharmaceuticals (SNOA), Reviva Pharmaceuticals (RVPH), and Enveric Biosciences (ENVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Avenue Therapeutics compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acurx PharmaceuticalsN/AN/A-$7.97M-$2.69N/A
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A

Acurx Pharmaceuticals currently has a consensus target price of $31.00, indicating a potential upside of 2,083.10%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Acurx Pharmaceuticals is more favorable than Avenue Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acurx Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score.

Company Overall Sentiment
Acurx Pharmaceuticals Neutral
Avenue Therapeutics Neutral

Acurx Pharmaceuticals has a beta of -2.02, suggesting that its stock price is 302% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market.

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Acurx Pharmaceuticals' return on equity of -124.73% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Acurx PharmaceuticalsN/A -124.73% -87.48%
Avenue Therapeutics N/A -471.57%-296.50%

Summary

Acurx Pharmaceuticals beats Avenue Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to Curanex Pharmaceuticals?

Curanex Pharmaceuticals (NASDAQ:CURX) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

17.3% of Avenue Therapeutics shares are held by institutional investors. 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Curanex Pharmaceuticals had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Curanex Pharmaceuticals and 0 mentions for Avenue Therapeutics. Curanex Pharmaceuticals' average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score.

Company Overall Sentiment
Curanex Pharmaceuticals Neutral
Avenue Therapeutics Neutral

Curanex Pharmaceuticals' return on equity of -82.07% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Curanex PharmaceuticalsN/A -82.07% -79.65%
Avenue Therapeutics N/A -471.57%-296.50%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curanex Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Curanex PharmaceuticalsN/AN/A-$4.22M-$7.80N/A
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A

Summary

Curanex Pharmaceuticals beats Avenue Therapeutics on 6 of the 8 factors compared between the two stocks.

How does Avenue Therapeutics compare to Sonoma Pharmaceuticals?

Avenue Therapeutics (NASDAQ:ATXI) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Avenue Therapeutics Neutral
Sonoma Pharmaceuticals Neutral

Avenue Therapeutics has a beta of -0.18, indicating that its share price is 118% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

Sonoma Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A
Sonoma Pharmaceuticals$19.53M0.32-$3.17M-$1.22N/A

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Avenue Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
Sonoma Pharmaceuticals -10.33%-21.41%-6.08%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Sonoma Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Sonoma Pharmaceuticals beats Avenue Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to Reviva Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Reviva Pharmaceuticals presently has a consensus price target of $75.00, indicating a potential upside of 14,050.94%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Avenue Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reviva PharmaceuticalsN/AN/A-$19.86M-$1.85N/A
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Reviva Pharmaceuticals and 0 mentions for Avenue Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score.

Company Overall Sentiment
Reviva Pharmaceuticals Neutral
Avenue Therapeutics Neutral

Reviva Pharmaceuticals' return on equity of -391.58% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Reviva PharmaceuticalsN/A -391.58% -119.08%
Avenue Therapeutics N/A -471.57%-296.50%

Reviva Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the broader market.

Summary

Reviva Pharmaceuticals beats Avenue Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Avenue Therapeutics compare to Enveric Biosciences?

Avenue Therapeutics (NASDAQ:ATXI) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Enveric Biosciences' return on equity of -168.04% beat Avenue Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avenue TherapeuticsN/A -471.57% -296.50%
Enveric Biosciences N/A -168.04%-145.95%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avenue TherapeuticsN/AN/A-$10.38M-$0.85N/A
Enveric BiosciencesN/AN/A-$8.77M-$12.65N/A

In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled Enveric Biosciences'average media sentiment score.

Company Overall Sentiment
Avenue Therapeutics Neutral
Enveric Biosciences Neutral

Avenue Therapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Summary

Enveric Biosciences beats Avenue Therapeutics on 5 of the 8 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATXI vs. The Competition

Export
MetricAvenue TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.79M$12.17B$7.17B$12.88B
Dividend YieldN/A2.59%2.53%8.57%
P/E Ratio0.03787.21272.9925.40
Price / SalesN/A759.13612.7397.00
Price / CashN/A94.8077.8252.27
Price / Book0.2812.4612.856.17
Net Income-$10.38M$2.82B$3.47B$349.50M
7 Day Performance20.46%3.80%1.24%-0.05%
1 Month Performance81.20%6.77%5.81%0.80%
1 Year Performance-16.23%10.44%25.75%15.62%

Avenue Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATXI
Avenue Therapeutics
N/A$0.54
-4.5%		N/A+3.6%$1.79MN/A0.034
ACXP
Acurx Pharmaceuticals
2.5088 of 5 stars		$1.43
-0.2%		$31.00
+2,072.4%		-66.2%$7.54MN/AN/A3
CURX
Curanex Pharmaceuticals
0.2225 of 5 stars		$4.71
+2.3%		N/A-96.1%$7.37MN/AN/AN/A
SNOA
Sonoma Pharmaceuticals
0.3871 of 5 stars		$1.33
-3.3%		N/A-71.4%$6.49M$19.53MN/A180
RVPH
Reviva Pharmaceuticals
1.7692 of 5 stars		$0.48
-5.0%		$75.00
+15,525.0%		-94.1%$6.29MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Congress Just Opened the Floodgates
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...
Awesomely | Sponsoredtc pixel
Wall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)
The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel